Skip to content

The clinical study of plasma activated water in the treatment of tuberculous empyema and extrapulmonary tuberculous body surface empyema

The clinical study of plasma activated water in the treatment of tuberculous empyema and extrapulmonary tuberculous body surface empyema

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400090459
Enrollment
Unknown
Registered
2024-09-30
Start date
2024-12-19
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Interventions

General drug treatment group:General medical treatment
Plasma activated water treatment group:Plasma activated water treatment
The combined treatment group:Conventional drug therapy and plasma activated water therapy

Sponsors

Tuberculosis Prevention and Treatment Hospital in Shaanxi Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-70 years old, sputum smear positive, culture positive for non-mycobacterium tuberculosis, and drug sensitivity test showed resistance to a variety of anti-mycobacterium drugs; 2. The patient is stable and able and willing to use the new plasma-activated water therapy; 3. No severe Coagulopathy, heart, brain, kidney and other important organ complications, able to tolerate and cooperate with the application, application, inhalation, perfusion, local injection or catheter administration; 4. No history of psychosis or epilepsy; 5. No immunosuppression and no immunosuppression in recent 3 months; 6. The blood glucose of the patients with diabetes mellitus was controlled less than 7.8 mmol/L 7. The subjects and their family members fully read, understand and sign the informed consent form;

Exclusion criteria

Exclusion criteria: 1.Severe heart, brain, kidney and other important organ complications, can not tolerate or have contraindications to interventional therapy; 2.The clinical diagnosis was severe Coagulopathy; 3.The clinical data were incomplete; 4.Did not sign the informed consent of surgery or can not cooperate with the treatment; 5.The patients were lost to follow-up, and the prognosis of the patients could not be judged;

Design outcomes

Primary

MeasureTime frame
objective response rate;

Secondary

MeasureTime frame
disease control rate;Negative conversion rate of tuberculosis bacteria in sputum culture;Chest CT changes;Number of Mycobacterium tuberculosis in drainage fluid;

Countries

China

Contacts

Public ContactWu Qianhong

Tuberculosis Prevention and Treatment Hospital in Shaanxi Province

15902969531@126.com+86 159 0296 9531

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026